Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Jiangning Gu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9258-9881; OpenAlex author ID A5018996994. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 16

  1. FOXM1, a super enhancer-associated gene, is related to poorer prognosis and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1007/s12013-024-01653-7↗
  2. Correction: FOXM1, a super enhancer-associated gene, is related to poorer prognosis and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1007/s12013-025-01710-9↗
  3. Correlation between Macrophage Polarization and PD-L1-Related Tumor Microenvironmental Alteration and Metastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2023/7971306↗
  4. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go? Co-author DOI 10.3389/fonc.2022.828223↗
  5. Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis. First author DOI 10.1097/md.0000000000026342↗
  6. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  7. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Co-author DOI 10.1038/s41420-020-0246-7↗
  8. Establishment and Investigation of a Multiple Gene Expression Signature to Predict Long-Term Survival in Pancreatic Cancer. First author DOI 10.1155/2020/1570862↗
  9. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. Co-author DOI 10.21037/jgo.2020.03.02↗
  10. Perineural invasion is related to p38 mitogen-activated protein kinase pathway activation and promotes tumor growth and chemoresistance in pancreatic cancer. Co-author DOI 10.1002/jcb.28457↗
  11. Corrigendum to "GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer" [Cancer Le… Co-author DOI 10.1016/j.canlet.2019.03.031↗
  12. MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo. Co-author DOI 10.1155/2019/8475389↗
  13. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway b… Co-author DOI 10.1002/jcb.26270↗
  14. MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. First author DOI 10.1016/j.canlet.2017.09.044↗
  15. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.06.016↗
  16. NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.4167↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hao Chen · 8 shared papers, 2015–2020 · strength 0.59
  2. Baiyong Shen · 7 shared papers, 2015–2020 · strength 0.52
  3. Chenghong Peng · 7 shared papers, 2015–2020 · strength 0.52
  4. Haifeng Luo · 4 shared papers, 2020–2023 · strength 0.51
  5. Dan Chen · 4 shared papers, 2020–2023 · strength 0.50
  6. Jian Wei Jiang · 2 shared papers, 2025 · strength 0.46
  7. Zhuo Yang · 2 shared papers, 2025 · strength 0.46
  8. Changmiao Wang · 2 shared papers, 2025 · strength 0.46
  9. Chenqi Wang · 3 shared papers, 2021–2023 · strength 0.41
  10. Guang Tan · 3 shared papers, 2020–2023 · strength 0.39
  11. Gang Wei · 5 shared papers, 2016–2020 · strength 0.38
  12. Di Wang · 4 shared papers, 2018–2020 · strength 0.34
  13. Dongfeng Cheng · 4 shared papers, 2018–2020 · strength 0.34
  14. Xiaxing Deng · 4 shared papers, 2015–2020 · strength 0.31
  15. Qian Zhan · 4 shared papers, 2016–2020 · strength 0.30
  16. Yi Zhu · 4 shared papers, 2015–2019 · strength 0.26
  17. Jiabin Jin · 3 shared papers, 2019–2020 · strength 0.26
  18. Yunlong Chen · 2 shared papers, 2021–2022 · strength 0.25
  19. Xiang 'Anthony' Chen · 2 shared papers, 2021–2022 · strength 0.25
  20. Youwei Zhu · 3 shared papers, 2018–2020 · strength 0.24
  21. Jian Du · 2 shared papers, 2020–2021 · strength 0.22
  22. Marija Trajkovic‐Arsic · 2 shared papers, 2019–2020 · strength 0.18
  23. Jens Thomas Siveke · 2 shared papers, 2019–2020 · strength 0.18
  24. Shi Chen · 2 shared papers, 2018–2020 · strength 0.17
  25. Xiaxing Deng · 2 shared papers, 2016–2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.